12/8 Taiwan BIO Weekly
2025-12-08 |
| Taiwan BIO Weekly |
| Taiwan's Jyong Biotech expands regional partnership with MoU signing in Vietnam Press release 6 December, 2025 Taiwan-based Jyong Biotech, specialising in the treatment of urinary system diseases, with an initial focus on the markets of the US, the EU and Asia, has entered into a non-binding Memorandum of Understanding (MoU) with a Vietnam-based pharmaceutical distribution company headquartered in Ho Chi Minh City, to evaluate the development and commercialisation of MCS-2 in the Vietnam pharmaceutical market. More... |
| President Lai highlights Taiwan's role in global medical tech at Healthcare+ Expo 4 December, 2025 President Lai Ching-te attended the opening of the Taiwan Healthcare+ Expo on Thursday, highlighting the integration of the nation's medical and technological sectors as a "strong partnership" that positions Taiwan for global expansion. He emphasized that Taiwan has developed a robust medical technology cluster and expressed hope that the industry will thrive locally while also reaching out to the global market, embodying the spirit of "Taiwan Can Help." More... |
| Unicocell Biomed's study on chronic kidney disease published in international journal 3 December, 2025 Unicocell Biomed (TW: 6794) announced that its CKD drug ELIXCYTE-CKD, which has completed Phase I/II trials, has shown significant real-world efficacy in a study published in Clinical and Translational Science. Comparing 34 patients in the ELIXCYTE trial with 170 matched patients receiving standard treatment, the study found that ELIXCYTE stem cell therapy slowed kidney function decline (eGFR) to 3.97% per year versus 18.37% in the standard care group, demonstrating its potential to markedly delay disease progression in advanced CKD patients. More... (in Chinese) |
| Lotus Pharmaceuticals submits new presbyopia drug VIZZ for approval in South Korea 2 December, 2025 Lotus Pharmaceuticals (TW: 1795) has submitted an NDA to South Korea's MFDS for VIZZ, its new treatment for adult presbyopia, marking the company's first NDA since partnering with LENZ in May 2025. The submission is based on positive Phase III CLARITY trial results, where VIZZ improved near vision within 30 minutes with effects lasting up to 10 hours, met all primary and secondary endpoints, and demonstrated good durability over 30,000 treatment days with no serious treatment-related adverse events. More... (in Chinese) |
| Powerchip Semiconductor Manufacturing's investee BioGate Precision Medicine reports new drug success 2 December, 2025 Amid strong order momentum at Powerchip Semiconductor (TW: 6770), its investee BioGate Precision Medicine also shared positive news. BioGate Precision Medicine announced that its independently developed, world-first PTHrP-targeting monoclonal antibody drug BGM-2121 has received approval from both the US FDA and Taiwan TFDA to initiate a Phase I clinical trial. The drug will initially target the most difficult-to-treat pancreatic cancer, and the company plans to independently bring the product to market, aiming at a large and lucrative global market. More... (in Chinese) |
| TaiGen teams up with Chinese partner to develop bronchial drug 2 December, 2025 TaiGen-KY (TW: 4157) announced that its subsidiaries, TaiGen Biotechnology and TaiGen Pharmaceutical R&D (Beijing), have signed a Greater China licensing agreement with China’s top-10 pharmaceutical company Kanghua Yuan to co-develop and commercialize TG-4318, a novel DPP1 inhibitor for bronchiectasis. The drug, currently in preclinical candidate evaluation, has potential best-in-class properties and is preparing to enter preclinical trials, targeting bronchiectasis as its primary indication. More... (in Chinese) |
| MegaPro Biomedical completes capital increase to advance development of new anti-cancer formulations 1 December, 2025 MegaPro Biomedical (TW: 6827) announced that its recent cash capital increase has been successfully completed, with all new shares fully subscribed. The newly issued common shares are expected to begin trading on the OTC market soon. The company also announced that its new anti-cancer formulation, MPB-1734, is advancing through process optimization, scale-up, and preparation for bioequivalence clinical trials. The company has completed preliminary pilot production with CDMO partners and is planning the related clinical studies with CRO support, aiming to complete manufacturing and trial readiness next year. These efforts are part of a broader strategy to advance its 505(b)(1) and 505(b)(2) technology platforms and support future product licensing and international collaborations. More... (in Chinese) |
| Taimed Biologics' HIV drug making inroads in Russia 1 December, 2025 Taimed Biologics (TW: 4147) announced that it has signed a supply agreement with Russian pharmaceutical company R-Pharm. Industry observers believe this will help strengthen Taimed's momentum in expanding the Russian market. Under the agreement, R-Pharm will be able to provide Trogarzo, Taimed's novel HIV treatment, to eligible patients with multidrug-resistant HIV-1 infection in Russia and related regions, in accordance with local regulations and authority requirements. More... (in Chinese) |
| Taiwan and Sweden explore roads towards smart and sustainable healthcare 1 December, 2025 National Cheng Kung University Hospital (NCKUH) hosted a high-level delegation from the Swedish Trade & Invest Council to explore collaboration opportunities in resilient hospital design and sustainable healthcare innovation. The visit, coordinated by NCKU's Shalun Healthcare and Innovation Park Implementation Office, focused on how Swedish expertise in flexible medical infrastructure can inform Taiwan's healthcare development. More... |
| Andros Pharmaceutical’s APC101 files for US clinical trial to enter global post-herpetic neuralgia market 1 December, 2025 Andros Pharmaceutical (TW: 6917) has submitted a Phase IIb/III clinical trial application to the US FDA for its APC101 spray for systemic post-herpetic neuralgia, following a previous submission in Australia. The global, multi-center trial will enroll 333 patients in Australia and the US using a randomized, double-blind, placebo-controlled design to evaluate efficacy and safety, with a competitive multi-center enrollment strategy aimed at accelerating clinical progress and advancing early commercialization and licensing. More... (in Chinese) |
| General Biologics accelerates growth with dual engines of precision medicine and wellness products 30 November, 2025 General Biologics (TW: 4117) is advancing a dual-engine strategy combining precision medicine and wellness products. By integrating equipment and reagents, expanding product lines such as CLIA chemiluminescence and fully automated molecular diagnostics, and applying AI to its liquid biopsy technology, the company is strengthening its offerings and partnerships, including with Fubon Life and Fubon Insurance for cancer testing. Its own brand, oh care, has also expanded across physical and online channels, positioning General Biologics for continued operational growth in the coming years. More... (in Chinese) |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Tel: +886 2 27836028 Fax: +886 2 27836027 Email: biotaiwan@gmail.com BIO Asia-Taiwan 2026 (15-19 July, 2026) ========================================= Taiwan Bio Industry Organization (Taiwan BIO) Room C229, 2F, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |